Kalvista Stops Phase II HAE Prophylactic Trial Following Liver Enzyme Concerns
But On-Demand Asset On Track
The US firm’s oral plasma kallikrein inhibitor was associated with liver elevations in a number of Phase II patients, prompting a trial termination and shift in focus to an on-demand program.
